A share price of Mirum Pharmaceuticals Inc [MIRM] is currently trading at $43.33, up 7.33%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The MIRM shares have gain 9.72% over the last week, with a monthly amount glided 31.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Mirum Pharmaceuticals Inc [NASDAQ: MIRM] stock has seen the most recent analyst activity on April 17, 2024, when Stifel initiated its Buy rating and assigned the stock a price target of $48. Previously, H.C. Wainwright reaffirmed its Buy rating on December 18, 2023, and dropped its price target to $58. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $60 on November 13, 2023. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $50 as its price target on October 24, 2023. In a note dated September 20, 2023, JMP Securities initiated an Mkt Outperform rating and provided a target price of $70 on this stock.
Mirum Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $23.14 and $41.88. Currently, Wall Street analysts expect the stock to reach $53.88 within the next 12 months. Mirum Pharmaceuticals Inc [NASDAQ: MIRM] shares were valued at $43.33 at the most recent close of the market. An investor can expect a potential return of 24.35% based on the average MIRM price forecast.
Analyzing the MIRM fundamentals
Trailing Twelve Months sales for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] were 224.00M which represents 119.07% growth. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -0.47%, Pretax Profit Margin comes in at -0.69%, and Net Profit Margin reading is -0.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -2.44 and Total Capital is -0.19. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.46 points at the first support level, and at 37.58 for the second support level. However, for the 1st resistance point, the stock is sitting at 45.45, and for the 2nd resistance point, it is at 47.57.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mirum Pharmaceuticals Inc [NASDAQ:MIRM] is 3.68. Also, the Quick Ratio is 3.47, while the Cash Ratio stands at 2.86. Considering the valuation of this stock, the price to sales ratio is 9.12, the price to book ratio is 8.69.
Transactions by insiders
Recent insider trading involved Howe Jolanda, SVP, GLOBAL CONTROLLER, that happened on Jul 02 ’24 when 375.0 shares were sold. CHIEF SCIENTIFIC OFFICER, Vig Pamela completed a deal on Jun 24 ’24 to sell 30559.0 shares. Meanwhile, Director Ramasastry Saira sold 5000.0 shares on Jun 05 ’24.
